| Compound |
Manufacture |
Target |
Comments |
Trial number |
| XL147 |
Exelixis |
pan-PI3K |
completed phase I |
NCT01240460 |
| PX866 |
Oncothyreon |
pan-PI3K |
ongoing phase II for patients with glioblastomamultiforme at time of first relapse or progression |
NCT01259869 |
| BKM120 |
Novartis |
pan-PI3K |
ongoing phase II trial for patients with recurrent Glioblastoma and activated PI3K pathway |
NCT01339052 |
| XL765 |
Exelixis |
PI3K/mTOR |
completed phase I |
NCT01240460 |
| KRX-0401 |
Keryx |
AKT |
ongoing phase II trial for recurrent/progressive malignant Gliomas |
NCT00590954 |
| AZD8055 |
AstraZeneca |
mTORC1/2 |
completed phase I trial for adults with recurrent gliomas |
NCT01316809 |
| RO4929097 |
Roche |
NOTCH |
ongoing phase II and pharmacodynamic trial for patients with recurrent/progressive Glioblastoma |
NCT01122901 |
| LY2157299 |
Eli Lilly |
TGFb |
ongoing phase 1b/2a study combining LY2157299 with standard Temozolomide-based Radiochemotherapy in patients with newly diagnosed malignant glioma |
NCT01220271 |
| TKI-258 |
Novartis |
RTK |
ongoing phaseI/II study for patients with recurrent or progressive Glioblastoma |
NCT01753713 NCT01972750 |
| Erlotinib |
Genentech/
Roche |
EGFR |
pilot study of EGFR inhibition using high dose administration of Erlotinib weekly for recurrent malignant Gliomas with EGFR variant III mutation |
NCT01257594 |
| BSI-201 |
Sanofi-Aventis |
PARP-1 |
ongoing phase I/II trial of BSI-201 plus temozolomide in patients with newly diagnosed malignant Glioma |
NCT00687765 |
| AZD2281 |
AstraZeneca |
PARP |
ongoing phase I trial of olaparib in combination with extended low-dose oral Temozolomide in patients with relapsed Glioblastoma |
NCT01390571 |
| LDE225 |
Novartis |
Smoothened |
ongoing phase Ib of oral LDE225 in combination with BKM 120 in patients with advanced solid tumors including recurrent GlioblastomaMultiforme |
NCT01576666 |
